

Quantity Limit

Antidiabetic Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist, Glucose-Dependent Insulinotropic Polypeptide (GIP) Receptor/Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist

Products Referenced by this Document

Drugs that are listed in the following table include both brand and generic and all dosage forms and strengths unless otherwise stated. Over-the-counter (OTC) products are not included unless otherwise stated.

Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist

Brand Name	Generic Name
Adlyxin	lixisenatide
Bydureon BCise	exenatide extended-release
Byetta	exenatide
Ozempic	semaglutide
Rybelsus	semaglutide
Trulicity	dulaglutide
Victoza	liraglutide

Reference number(s)
4525-H

Glucose-Dependent Insulinotropic Polypeptide (GIP) Receptor and Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist

Brand Name	Generic Name
Mounjaro	tirzepatide

Indications

FDA-approved Indications

Adlyxin

Adlyxin is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

Limitations of Use

- Adlyxin has not been studied in patients with chronic pancreatitis or a history of unexplained pancreatitis. Consider other antidiabetic therapies in patients with a history of pancreatitis.
- Adlyxin should not be used in patients with type 1 diabetes mellitus.
- Adlyxin has not been studied in patients with gastroparesis and is not recommended in patients with gastroparesis.

Bydureon BCise

Bydureon BCise is indicated as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients aged 10 years and older with type 2 diabetes mellitus.

Limitations of Use

- Bydureon BCise is not recommended as first-line therapy for patients who have inadequate glycemic control on diet and exercise because of the uncertain relevance of the rat thyroid C-cell tumor findings to humans.
- Bydureon BCise is not indicated for use in patients with type 1 diabetes mellitus.
- Bydureon BCise is an extended-release formulation of exenatide and should not be used with other products containing the active ingredient exenatide.
- Bydureon BCise has not been studied in patients with a history of pancreatitis. Consider other antidiabetic therapies in patients with a history of pancreatitis.

Byetta

Byetta is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

Limitations of Use

- Byetta is not indicated for use in patients with type 1 diabetes.
- Byetta contains exenatide and should not be used with other products containing the active ingredient exenatide.

Reference number(s)
4525-H

- Byetta has not been studied in patients with a history of pancreatitis. Consider other antidiabetic therapies in patients with a history of pancreatitis.

Mounjaro

Mounjaro is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

Limitations of Use

- Mounjaro has not been studied in patients with a history of pancreatitis.
- Mounjaro is not indicated for use in patients with type 1 diabetes mellitus.

Ozempic

Ozempic is indicated:

- as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
- to reduce the risk of major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke) in adults with type 2 diabetes mellitus and established cardiovascular disease.

Limitations of Use

- Ozempic has not been studied in patients with a history of pancreatitis. Consider other antidiabetic therapies in patients with a history of pancreatitis.
- Ozempic is not indicated for use in patients with type 1 diabetes mellitus.

Rybelsus

Rybelsus is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

Limitations of Use

- Rybelsus is not indicated for use in patients with type 1 diabetes mellitus.

Trulicity

Trulicity is indicated:

- as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients 10 years of age and older with type 2 diabetes mellitus.
- to reduce the risk of major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke) in adults with type 2 diabetes mellitus who have established cardiovascular disease or multiple cardiovascular risk factors.

Limitations of Use

- Trulicity has not been studied in patients with a history of pancreatitis. Consider other antidiabetic therapies in patients with a history of pancreatitis.
- Trulicity should not be used in patients with type 1 diabetes mellitus.
- Trulicity has not been studied in patients with severe gastrointestinal disease, including severe gastroparesis and is therefore not recommended in these patients.

Reference number(s)
4525-H

Victoza

Victoza is indicated:

- as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients aged 10 years and older with type 2 diabetes mellitus,
- to reduce the risk of major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke) in adults with type 2 diabetes mellitus and established cardiovascular disease.

Limitations of Use

- Victoza should not be used in patients with type 1 diabetes mellitus.
- Victoza contains liraglutide and should not be coadministered with other liraglutide-containing products.

Initial Limit Criteria

Limits do not accumulate together; patient is allowed the maximum limit for each drug and strength.

PLEASE NOTE: Since manufacturer package sizes may vary, it is the discretion of the dispensing pharmacy to fill quantities per package size up to these quantity limits. In such cases the filling limit and day supply may be less than what is indicated.

The duration of 25 days is used for a 30-day fill period and 75 days is used for a 90-day fill period to allow time for refill processing OR the duration of 21 days is used for a 28-day fill period and 63 days is used for an 84-day fill period to allow time for refill processing.

Drug	Maximum Dosing	Package Size(s)	1 Month Limit 3 Months Limit
Adlyxin	20 mcg daily	Starter pack - 2 pens (1 pen of 10 mcg, 1 pen of 20 mcg), 14 doses per pen, 3 mL each Maintenance pack - 2 pens of 20 mcg, 14 doses per pen, 3 mL each	2 prefilled pens (6 mL) / 21 days 6 prefilled pens (18 mL) / 63 days
Bydureon BCISE	2 mg once weekly	Carton of 4 single-dose autoinjectors (2 mg/0.85 mL each)	4 auto-injectors (3.4 mL) / 21 days 12 auto-injectors (10.2 mL) / 63 days
Byetta	10 mcg twice daily	5 mcg dose, 60 doses, 1.2 mL prefilled pen	1 prefilled pen (1.2 mL) / 25 days 3 prefilled pens (3.6 mL) / 75 days
Byetta	10 mcg twice daily	10 mcg dose, 60 doses, 2.4 mL prefilled pen	1 prefilled pen (2.4 mL) / 25 days 3 prefilled pens (7.2 mL) / 75 days

Drug	Maximum Dosing	Package Size(s)	1 Month Limit 3 Months Limit
Mounjaro	15 mg once weekly	Carton of 4 pre-filled single-dose pens or 1 single-dose vial (0.5 mL each) of 2.5 mg/0.5 mL, 5 mg/0.5 mL, 7.5 mg/0.5 mL, 10 mg/0.5 mL, 12.5 mg/0.5 mL, 15 mg/0.5 mL	4 pre-filled single-dose pens or 4 single-dose vials (2 mL) / 21 days 12 pre-filled single-dose pens or 12 single-dose vials (6 mL) / 63 days
Ozempic	2 mg once weekly	Carton of 1 pen (2 mg/1.5 mL)	1 prefilled pen (1.5 mL) / 21 days 3 prefilled pens (4.5 mL) / 63 days
Ozempic	2 mg once weekly	Carton of 1 pen (2 mg/3 mL)	1 prefilled pen (3 mL) / 21 days 3 prefilled pens (9 mL) / 63 days
Ozempic	2 mg once weekly	Carton of 1 pen (4 mg/3 mL)	1 prefilled pen (3 mL) / 21 days 3 prefilled pens (9 mL) / 63 days
Ozempic	2 mg once weekly	Carton of 1 pen (8 mg/3 mL)	1 prefilled pen (3 mL) / 21 days 3 prefilled pens (9 mL) / 63 days
Rybelsus (R2 formulation)	9 mg once daily	1.5 mg, 4 mg, 9 mg in bottles of 30 tablets	30 tablets / 25 days 90 tablets / 75 days
Rybelsus (R1 formulation)	14 mg once daily	3 mg, 7 mg, 14 mg in bottles of 30 tablets	30 tablets / 25 days 90 tablets / 75 days
Trulicity	4.5 mg once weekly	0.75 mg/0.5 mL, 1.5 mg/0.5 mL, 3 mg/0.5 mL, 4.5 mg/0.5 mL in cartons of 4 single-dose pens (0.5 mL each)	4 pens (2 mL) / 21 days 12 pens (6 mL) / 63 days
Victoza	1.8 mg once daily	Package of 2 or 3 pens (18 mg/3 mL each)	3 pens (9 mL) / 25 days 9 pens (27 mL) / 75 days

References

1. Adlyxin [package insert]. Bridgewater, NJ: Sanofi-Aventis U.S. LLC; June 2022.
2. Bydureon BCise [package insert]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; May 2023.
3. Byetta [package insert]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; December 2022.
4. Mounjaro [package insert]. Indianapolis, IN: Lilly USA, LLC; July 2023.
5. Ozempic [package insert]. Plainsboro, NJ: Novo-Nordisk Inc.; September 2023.
6. Rybelsus [package insert]. Plainsboro, NJ: Novo-Nordisk Inc.; December 2024.
7. Trulicity [package insert]. Indianapolis, IN: Eli Lilly and Company; December 2022.
8. Victoza [package insert]. Plainsboro, NJ: Novo Nordisk Inc.; July 2023.
9. Lexicomp Online, AHFS DI (Adult and Pediatric) Online. Waltham, MA: UpToDate, Inc.; 2024. <https://online.lexi.com>. Accessed March 11, 2024.
10. Micromedex® (electronic version). Merative, Ann Arbor, Michigan, USA. Available at: <https://www.micromedexsolutions.com/> (cited: 03/11/2024).